지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한약학회 Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea 제25권 제5호
- 발행연도
- 2002.1
- 수록면
- 655 - 663 (9page)
이용수
초록· 키워드
오류제보하기
Liver fibrosis is a prepathological state wherein damaged liver tissues in chronic liver diseases, such as hepatitis, are not repaired to normal tissues, but converted to fibrous tissue. 5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz), a cancer chemopreventive agent, is effective against a wide variety of chemical carcinogens. Recently, we reported that oltipraz inhibits liver fibrogenesis (Kang et al., 2002). In the present study, the effects of oltipraz in combination with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDb) on dimethylnitrosamine (DMN)-induced liver fibrogenesis were assessed in rats. Oltipraz (30 mg/kg body weight, po, 3 times per week for 4 weeks) was found to inhibit the increases in plasma ALT, AST and bilirubin by DMN, whereas DDB (30 mg/kg body weight, po, 3 times per week for 4 weeks) attenuated the increases in the plasma ALT and bilirubin. The lowered plasma protein and albumin contents in DMN-treated rats were completely restored by oltipraz, but not by DDB. DDB decreases liver cell injury and inflammation through inhibition of nuclear factor-kB. DMN increased the accumulation of liver collagen, as indicated by the increase in the 4-hydroxyproline content in liver homogenates, which was reduced by treatment with oltipraz, but not by DDB. Given the differential effect between oltipraz and DDB, the potential enhancement of antifibrotic efficacy by the drugs was assessed in the animal model. Despite the minimal effect of DDB on DMN-induced fibrogenesis, DDB (5-25 mg/kg), administered together with oltipraz (25-5 mg/kg), showed an additive protective effect against hepatotoxicity and fibrosis induced by DMN, which was shown by the blood chemistry parameters and histopathological analysis. The adequate composition ratio of oltipraz to DDB was 5:1. These results provide information on the pharmaceutical composition, comprising of oltipraz and DDB as the active components, for the treatment and/or prevention of liver fibrosis and cirrhosis.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Dimethyl-4 , 4`-Dimethoxy-5 , 6 , 5 , 6`-Dimethylene Dioxybiphenyl-2 , 2`-Dicarboxylate ( PMC ) 와 마늘유 복합제의 흰쥐에서의 급성독성시험 ( Acute Toxicity Test of Dimethyl-4 , 4`-Dimethoxy-5 , 6 , 5 , 6`-Dimethylene Dioxybiphenyl-2 , 2`-Dicarboxylate in Combination With Garlic Oil in Rats )
한국독성학회지
1994 .06
-
Oltipraz inhibits dimethylnitrosamine-induced liver fibrosis through suppression of transforming growth factor-beta 1 and tumor necrosis factor-alpha expression
대한약학회 학술대회
2001 .01
-
새로운 간염치료제인 수용성 DDB 유도체 ( DDB-S ) 의 항원성 평가 ( Antigenicity of a water soluble dimethyl dimethoxy biphenylate derivative ( ddb-s ) , a new antihepatitis agent
한국독성학회지
1998 .09
-
비페닐디메칠디카르복실레이트 연질캅셀제의 설계 및 제제학적 평가
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
1996 .01
-
Studies of the murine DDB2 splicing variants
한국실험동물학회 학술발표대회 논문집
2005 .06
-
염산 DDB-S가 랫드의 생식독성에 미치는 영향에 관한 연구
Toxicological Research
2003 .03
-
HPLC Analysis, Stability, Blood Partition, and Protein Binding of an Antifibrotic Agent, Oltipraz
대한약학회 학술대회
2001 .01
-
Biphenyl Dimethyl Dicarboxylate가 간내 Cytochrome $P_{450}$ 1A1과 2Bl 및 $CCl_4$ 유도 간독성에 미치는 영향
약학회지
1999 .01
-
Effect of 2-Methylaminoethyl-4,4'-Dimethoxy-5, 6, 5' ,6'-Dimethylenedioxybiphenyl-2-Carboxylic Acid-2'-Carboxylate Monohydrochloride (DDB-S) on Indocyanine Green (ICG) Clearance in Rats
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2005 .01
-
Influence of Temperature and pH on the Stability of Dimethoxy Biphenyl Monocarboxylate${\cdot}$HCl Solutions
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2001 .01
-
비글개에서 수용성 DDB 유도체의 3개월 반복투여독성에 관한 연구 ( Study for Three-months Subacute Toxicity of Water-Soluble DDB Derivative in Beagle Dogs )
Toxicological Research
2000 .09
-
레베셀(DDB-S)주의 안전성, 내약성 및 약동학적 특성평가
대한임상약리학회 학술대회
2001 .01
-
C/EBP$\beta$ mediated inhibition of PAH-inducible CYPlAl expression by Oltipraz, a cancer chemopreventive agent
대한약학회 학술대회
2003 .01
-
수용성 DDB 유도체의 3개월 반복투여독성에 관한 연구 ( Three Months Subacute Toxicity of Water Soluble Dimethyl Dimethoxy Biphenylate Derivative in Rats )
Toxicological Research
2000 .06
-
비글개에서 수용성 DDB 유도체의 급성 독성 및 아급성 독성시험 연구
Laboratory Animal Research
1998 .06
-
In vitro inhibition of DDB toward CYP3A4 : inhibitory patterns are substrate - dependent
대한약학회 학술대회
2000 .01
-
In vivo metabolism of 2-methylaminoethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylenedioxybiphenyl-2′-carboxy-2-carboxylate (DDB-S) in rats using deutrium labeled compound
대한약학회 학술대회
2003 .01
-
오미자 활성성분 DDB의 NF-κB 신호 전달 및 염증물질 발현 조절
Immune Network
2006 .03
-
Interferon Signal Transduction of Biphenyl Dimethyl Dicarboxylate/Amantadine and Anti-HBV Activity in HepG2 2.2.15
Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea
2006 .01
-
New Splicing Variants of the Murine Damaged DNA Binding 2
Laboratory Animal Research
2010 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0